

Index

A

ABCB1, 119
ABCC4, 119
ABL, 157
Acute myeloid leukemia (AML), 38
Acute promyelocytic leukemia (APL), 157
AML. *See* Acute myeloid leukemia
APL. *See* Acute promyelocytic leukemia
ASD. *See* Autism spectrum disorder
ATAC-Seq, 33
ATM, 134
Autism spectrum disorder (ASD)
 copy number variation, 99–100, 106, 108
 epidemiology, 97–98
 gene discovery, 103–104
 gene mutation patterns, 103
 heritability, 98
 heterozygous variants, 104
 homozygous variants, 104–105
 intellectual disability comorbidity, 91–92
 karyotyping, 98–99
 large-scale sequencing datasets, 105–106
 missense variants, 101, 103
 protein-truncating variants, 100–101, 103–104, 106
 somatic mutations, 105
 whole-exome sequencing, 101–103
 whole-genome sequencing, 106–108

B

BCR, 157
BRAF, 150
BRCA1, 73–74, 134–135, 164
BRCA2, 73–74, 134–135, 164
Breast cancer, risk assessment with high-throughput sequencing, 73–74

C

CAF. *See* Cancer-associated fibroblast
Cancer genomics. *See also* Circulating tumor cell;
 Circulating tumor DNA; Clinical next-
 generation sequencing; Whole-genome
 sequencing
 historical perspective, 157–160
 next-generation sequencing
 clinical applications, 63, 164–165
 large-scale discovery efforts, 161–164
 overview, 160–161
Cancer-associated fibroblast (CAF), 39
CASK, 84

CHARM, 49
CHD8, 103, 105
Chorionic villous sampling (CVS), 77
10X Chromium system, 32
Chronic myeloid leukemia (CML), 157
Circulating tumor cell (CTC)
 isolation, 147
 next-generation sequencing
 clinical applications
 genotyping, 150, 165–166
 minimal residual disease, 151
 tumor burden monitoring, 150–151
 gene expression profiling, 148–149
 mutational profiling, 147–148
 overview, 147
Circulating tumor DNA (ctDNA)
 analytical techniques and challenges, 144–146
 next-generation sequencing
 clinical applications
 genotyping, 150
 minimal residual disease, 151
 tumor burden monitoring, 150–151
 targeted sequencing, 146, 165–166
 whole-genome sequencing, 146
 overview, 143–144
CITE-Seq, 31
CLCN4, 86
Clinical next-generation sequencing
 analytic validity, 65
 analytical sensitivity, 67
 analytical specificity, 67–68
 cancer genotyping and sequencing, 63
 clinical utility, 67
 confirmatory testing, 66–67
 data
 analysis, 66
 coverage, 65–66
 reporting and storage, 68
 diagnostics test developmental flowchart, 61
 noninvasive prenatal screening, 62–63
 platforms, 60–61
 regulatory requirements, 63–64
 sample handling, 64–65
 targeted gene panels, 61–62
 test development and validation, 65
 turnaround time, 65
 whole-exome sequencing, 62
 whole-genome sequencing, 62
CML. *See* Chronic myeloid leukemia
CNKS2, 86

Index

- CNSKR, 86
CNV. *See* Copy number variant
Copy number variant (CNV)
 autism spectrum disorder, 99–100, 106, 108
 intellectual disability genes, 88–90
 single-cell profiling in cancer, 34–35, 38, 40
 whole-genome sequencing in cancer, 131–133
CRISPR, 33, 120
CTC. *See* Circulating tumor cell
ctDNA. *See* Circulating tumor DNA
CVS. *See* Chorionic villous sampling
CYP2A6, 117–118
CYP2C9, 121
CYP2C19, 119
CYP2D6, 117–118, 120
- D**
Data storage and transfer, genomics, 182–183
Diabetes, heritability, 78
DNAJB1, 14
- E**
EGFR. *See* Epidermal growth factor receptor
EMT. *See* Epithelial mesenchymal transition
ENCODE project, 16, 89, 135
Epidermal growth factor receptor (EGFR), 63
Epigenetics
 DNA methylation in gene regulation, 48–51
 genome-wide detection of DNA methylation, 51
 reduced representation bisulfite sequencing, 53
 single-cell sequencing studies, 33, 54–55
 whole-genome bisulfite sequencing, 49–52
Epithelial mesenchymal transition (EMT), tumors, 39
ESR1, 148, 151
Ethics, genetics data, 183–188
- F**
FMRI, 99, 105
FMRP, 105
FRMPD4, 86
- G**
GEMCode, 13
Genetic Information Nondiscrimination Act (GINA), 184
Genome-wide association study (GWAS), disease risk
 assessment, 78–81
GINA. *See* Genetic Information Nondiscrimination Act
GridION, 12
GSTM1, 118
GSTT1, 118
GWAS. *See* Genome-wide association study
- H**
HBGRD. *See* Human Biobanks and Genetic Research
 Database
- HCFC1*, 89
HER2, 150
HiSeq X, 10–11
Homologous recombination, cancer defects, 134–135
Human Biobanks and Genetic Research Database
 (HBGRD), 172
- I**
ID. *See* Intellectual disability
IDH1, 162
Intellectual disability (ID)
 autosomal recessive intellectual disability, 86–87
 copy number variation detection, 89–90
 diagnostics, 90–91
 epidemiology, 83–84
 prospects for next-generation sequencing, 91–93
 whole-exome sequencing, 87–88
 whole-genome sequencing, 88–89
 X-linked intellectual disability
 gene discovery, 84–85
 targeted sequencing studies, 85–86
IQSEC2, 89
- K**
KATNAL2, 103
KCNQ1, 90
KLHL15, 86
KRAS, 63, 150–151
- L**
LARP7, 87
LASIL, 86
- M**
MECP2, 91
Minimal residual disease, next-generation sequencing in
 detection and monitoring, 151
MinION, 12
MLH1, 134
Moore's Law, 181
MSH2, 134
MSH6, 134
- N**
Neurofibromatosis type 1, risk assessment with
 high-throughput sequencing, 72–73
NF1, 72, 99
NIPS. *See* Noninvasive prenatal screening
NLGN3, 99
NLGN4X, 99
NOME-Seq, 50
Noninvasive prenatal screening (NIPS), 62–63, 77
NovaSeq 6000, 11–12, 15

- O**
- OATP1B1, 119
 - Oncology Research Information Exchange Network (ORIEN), 15
 - ORIEN. *See* Oncology Research Information Exchange Network
 - Ovarian cancer, risk assessment with high-throughput sequencing, 73–74
- P**
- Pacific Biosciences RS, 12
 - PALB2*, 134
 - PDHI*, 88
 - Perturb-Seq, 32
 - PGD. *See* Preimplantation genetic diagnosis
 - Pharmacogenetics
 - next-generation sequencing
 - clinical implementation, 120–122
 - diagnostic testing, 120–121
 - functional characterization of single-functional variants, 120
 - functional relevance prediction using bioinformatics, 119
 - platform technical limitations, 116–119
 - rare functional variants
 - statistical challenges, 121–122
 - targeted strategies, 115–116
 - variant discovery, 114–115
 - overview, 113–114
 - PIK3CA*, 150
 - PML*, 158
 - PMS2*, 134
 - PPF1A1*, 90
 - Preimplantation genetic diagnosis (PGD), 77
 - Privacy, genetics data, 183–188
 - PRKACA*, 14
 - PromethION, 12
 - Protein-truncating variant (PTV), autism spectrum disorders, 100–101, 103–104, 106
 - PSD95, 86
 - PTV. *See* Protein-truncating variant
- R**
- RAB19*, 90
 - RAD50*, 134
 - RAD51*, 134
 - RARA*, 158
 - REAP-Seq, 31–32
 - Reduced representation bisulfite sequencing (RRBS), 53
 - REST, 105
 - RET, 131
 - Return of results, next-generation sequencing
 - adults, 173–174
 - family members of deceased individuals, 177
 - oversight, 171–172
 - pediatrics, 175–176
 - population studies, 177–178
 - RLIM*, 86
 - RRBS. *See* Reduced representation bisulfite sequencing
- S**
- SAKE. *See* scRNA-Seq analysis and clustering evaluation
 - Sanger sequencing
 - data analysis, 2–3
 - historical perspective, 1–2
 - principles, 1–2
 - SBS. *See* Sequencing by synthesis
 - SCN2A*, 103, 105
 - SCNA2*, 88
 - scRNA-Seq analysis and clustering evaluation (SAKE), 27
 - Sequencing by synthesis (SBS)
 - combined analysis with single-molecule sequencing data, 7
 - data analysis, 4–5
 - detection of nucleotide incorporation, 3–4
 - principles, 3
 - SETD2*, 105
 - SHANK2*, 90
 - SHANK3*, 84
 - Single-nucleotide polymorphism (SNP)
 - genome-wide association study, 79
 - intellectual disability genes, 88–90
 - Single-cell sequencing
 - applications, 22
 - cancer
 - copy number variation profiling, 34–35, 38, 40
 - rare cells, 40
 - single-nucleus sequencing, 36–37
 - transcription studies, 38–40
 - cell isolation and amplification, 29
 - droplet capture, 24–26
 - embryology and development studies, 30
 - epigenetics studies, 33, 54–55
 - immune repertoire profiling, 30–31
 - megacell experiments, 29, 41
 - neurobiology studies, 34
 - platforms, 22–23
 - prospects, 40–42
 - protocols, 23
 - reverse transcription, 23–24
 - transcriptomics, 26–27
 - t-SNE visualization of clusters, 27–28, 30, 32
 - Single-molecule sequencing (SMS)
 - combined analysis with sequencing by synthesis data, 7
 - data analysis, 7–8
 - fluorescence-based sequencing, 6
 - nanopore-based sequencing, 6–7
 - principles, 5–6
 - SLCO1B1*, 119
 - SMS. *See* Single-molecule sequencing
 - SNP. *See* Single-nucleotide polymorphism
 - STXBP1*, 84
 - SYNGAP1*, 84

Index

T

T-cell receptor (TCR), immune repertoire profiling
in single cells, 30–31
TCF4, 90
TCGA. *See* The Cancer Genome Atlas
TCR. *See* T-cell receptor
t-distributed stochastic neighbor embedding (t-SNE),
27–28, 30, 32
TENM3, 89
TERT, 135
The Cancer Genome Atlas (TCGA), 15–16, 59, 163
TMB. *See* Total mutational burden
Total mutational burden (TMB), cancer, 133
TSC1, 99
TSC2, 99
t-SNE. *See* t-distributed stochastic neighbor embedding

U

UMI. *See* Unique molecular identifier
Unique molecular identifier (UMI), 23–24, 27
USP27X, 86

V

VKORC1, 121
VolTRAX, 12

W

WES. *See* Whole-exome sequencing
WGBS. *See* Whole-genome bisulfite sequencing

WGS. *See* Whole-genome sequencing
Whole-exome sequencing (WES)
autism spectrum disorder, 101–103
intellectual disability gene identification, 87–88
Whole-genome bisulfite sequencing (WGBS), 49–52
Whole-genome sequencing (WGS)
autism spectrum disorder, 106–108
circulating tumor DNA, 146
intellectual disability gene identification, 88–89
oncology
clinical characterization, 130–131
digital karyotyping, 131–133
genomic instability, 133–134
historical perspective, 129–130
homologous recombination deficiency,
134–135
immunology, 136
mismatch repair deficiency, 134
noncoding region variation, 135
prospects, 136–138
whole-genome and transcriptome analysis,
137–138
Whole-transcriptome sequencing (WTS), 135–136
WTS. *See* Whole-transcriptome sequencing

Y

YY1, 89

Z

ZBTB40, 87